BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18461633)

  • 1. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion.
    Noh YH; Lee SM; Kim EJ; Kim DY; Lee H; Lee JH; Lee JH; Park SY; Koo JH; Wang JH; Lim IJ; Choi SB
    Diabetes Metab Res Rev; 2008; 24(5):384-91. PubMed ID: 18461633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.
    Parkner T; Møller MK; Chen JW; Laursen T; Jørgensen C; Smedegaard JS; Lauritzen T; Christiansen JS
    Diabetes Obes Metab; 2008 Jul; 10(7):556-63. PubMed ID: 17593233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous insulin infusion is more effective than multiple daily insulin injections in preventing albumin excretion rate increase in Type 1 diabetic patients.
    Lepore G; Bruttomesso D; Bonomo M; Dodesini AR; Costa S; Meneghini E; Corsi A; Nosari I; Trevisan R
    Diabet Med; 2009 Jun; 26(6):602-8. PubMed ID: 19538235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of short-term intensive insulin therapy on daily insulin requirement in poorly controlled type 2 diabetes patients].
    Mozdzan M; Mozdzan M; Loba J; Markuszewski L; Ruxer J
    Wiad Lek; 2006; 59(3-4):203-7. PubMed ID: 16813265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory cytokines in insulin-treated patients with type 2 diabetes.
    Mavridis G; Souliou E; Diza E; Symeonidis G; Pastore F; Vassiliou AM; Karamitsos D
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):471-6. PubMed ID: 17976964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system.
    Mozdzan M; Ruxer J; Loba J; Siejka A; Markuszewski L
    Adv Med Sci; 2006; 51():133-6. PubMed ID: 17357293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
    Pickup JC; Sutton AJ
    Diabet Med; 2008 Jul; 25(7):765-74. PubMed ID: 18644063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.
    Choi SB; Lee JH; Lee JH; Kim S; Han SD; Kim IH; Noh YH
    Diabetes Metab Res Rev; 2013 Sep; 29(6):473-82. PubMed ID: 23592489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluating the feature of hypoglycemia detected by continuous glucose monitoring system during temporary continuous subcutaneous insulin infusion in type 2 diabetes patients].
    Li M; Zhou J; Bo YQ; Lu W; Jia WP; Xiang KS
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1679-82. PubMed ID: 19024537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart.
    Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
    Scand J Clin Lab Invest; 2008; 68(8):739-44. PubMed ID: 19016075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nocturnal hypoglycaemia in Type 1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associations.
    Wentholt IM; Maran A; Masurel N; Heine RJ; Hoekstra JB; DeVries JH
    Diabet Med; 2007 May; 24(5):527-32. PubMed ID: 17381503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.